- Home
- PMO vs IMMP Comparison
PMO vs IMMP Comparison
Compare PMO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMO
- IMMP
- Stock Information
- Founded
- PMO 1993
- IMMP 1987
- Country
- PMO United States
- IMMP Australia
- Employees
- PMO N/A
- IMMP N/A
- Industry
- PMO Finance Companies
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PMO Finance
- IMMP Health Care
- Exchange
- PMO Nasdaq
- IMMP Nasdaq
- Market Cap
- PMO 291.4M
- IMMP 256.1M
- IPO Year
- PMO N/A
- IMMP N/A
- Fundamental
- Price
- PMO $10.39
- IMMP $1.88
- Analyst Decision
- PMO
- IMMP Buy
- Analyst Count
- PMO 0
- IMMP 1
- Target Price
- PMO N/A
- IMMP $7.00
- AVG Volume (30 Days)
- PMO 99.0K
- IMMP 142.4K
- Earning Date
- PMO 01-01-0001
- IMMP 02-22-2026
- Dividend Yield
- PMO 4.10%
- IMMP N/A
- EPS Growth
- PMO N/A
- IMMP N/A
- EPS
- PMO 0.42
- IMMP N/A
- Revenue
- PMO N/A
- IMMP $3,306,742.00
- Revenue This Year
- PMO N/A
- IMMP N/A
- Revenue Next Year
- PMO N/A
- IMMP N/A
- P/E Ratio
- PMO $24.38
- IMMP N/A
- Revenue Growth
- PMO N/A
- IMMP 31.28
- 52 Week Low
- PMO $8.57
- IMMP $1.32
- 52 Week High
- PMO $10.68
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- PMO 55.97
- IMMP 51.34
- Support Level
- PMO $10.36
- IMMP $1.78
- Resistance Level
- PMO $10.45
- IMMP $2.08
- Average True Range (ATR)
- PMO 0.07
- IMMP 0.08
- MACD
- PMO -0.00
- IMMP -0.01
- Stochastic Oscillator
- PMO 70.59
- IMMP 51.16
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.